Antares Pharma Beats Up on Analysts Yet Again

Seth Jayson, The Motley Fool
Updated

Antares Pharma (NAS: ATRS) reported earnings on Nov. 7. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Antares Pharma beat slightly on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share increased.


Margins shrank across the board.

Revenue details
 Antares Pharma reported revenue of $5.7 million. The three analysts polled by S&P Capital IQ expected to see a top line of $5.6 million on the same basis. GAAP reported sales were 45% higher than the prior-year quarter's $3.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.03. The one earnings estimate compiled by S&P Capital IQ predicted -$0.03 per share. GAAP EPS were -$0.03 for Q3 compared to -$0.01 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 42.0%, 1,190 basis points worse than the prior-year quarter. Operating margin was -61.9%, 2,960 basis points worse than the prior-year quarter. Net margin was -62.2%, 2,900 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $6.4 million. On the bottom line, the average EPS estimate is -$0.03.

Next year's average estimate for revenue is $23.5 million. The average EPS estimate is -$0.08.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 177 members out of 191 rating the stock outperform, and 14 members rating it underperform. Among 21 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 16 give Antares Pharma a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is buy, with an average price target of $5.00.

The article Antares Pharma Beats Up on Analysts Yet Again originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement